Trials / Unknown
UnknownNCT01292369
Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study
Observational Study Aimed to Characterize a System for Breast and Colon Cancer Diagnosis by Breath Testing - NaNose Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 560 (estimated)
- Sponsor
- Rambam Health Care Campus · Academic / Other
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
The concept of breath testing for various diseases has been around since ancient greece. It has been hypothesized that cancer is generating a unique pattern of compounds in patients' breath. This study is trying to characterize a novel system, based on nanoparticles technology, for cancer diagnosis through breath samples.
Detailed description
Cancer is accompanied by increased oxidative stress and induction of polymorphic cytochrome P- 450 mixed oxidase enzymes (CYP). Both processes affect the abundance of volatile organic compounds (VOCs) in the breath because oxidative stress causes lipid peroxidation of polyunsaturated fatty acids in membranes, producing alkanes and methylalkanes which are catabolized by CYP. In the Technion labs, a new system for breath samples diagnosis, is being developed. The system is based on Nanoparticles technology. The current study will try to identify colon and breast cancer patients through their breath samples and discriminate them from healthy individuals. Men and women coming for colonoscopy or breast biopsy will be recruited for the study. Breath samples will be taken from all volunteers before the medical test. Subjects with positive cancer results by biopsy will be the test groups for both diseases, all others will be the control. The research goal is to test the NaNose system ability to discriminate between healthy and sick.
Conditions
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-10-01
- Completion
- 2011-12-01
- First posted
- 2011-02-09
- Last updated
- 2011-08-18
Locations
2 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT01292369. Inclusion in this directory is not an endorsement.